Medical research is exploring the intersection of GLP-1 receptor agonists and oncology, triggering debate over their potential role in cancer treatment.
Researchers have identified a hidden liver mechanism that targets LDL receptors, offering a potential new alternative to statin drugs for cholesterol control.